INTRODUCTION
Macrophage activation syndrome (MAS) is a potentially fatal complication of systemic juvenile idiopathic arthritis (sJIA), whose pathophysiologic hallmark is an exaggerated but ineffective immune response involving excessive macrophage and T-cell activation that produce high levels of proinflammatory cytokines (1, 2) . The cardinal clinical symptoms and signs of MAS are prolonged high fever, hepatosplenomegaly, neurologic dysfunction, and hemorrhagic manifestations.
Characteristic laboratory abnormalities include pancytopenia, elevated serum liver enzymes, triglycerides, lactate dehydrogenase and ferritin, and low fibrinogen. Although macrophage hemophagocytosis is often seen on bone marrow examination, this finding may be absent, particularly in the initial stages of the syndrome (3) (4) (5) (6) . The presence of hemophagocytosis may be governed by a relative paucity of the anti-inflammatory cytokine IL-10 (7).
The estimated prevalence of MAS in sJIA is around 10%. However, recent evidence suggests that the syndrome may occur subclinically in an additional 30-40%of sJIA patients (8, 9) . Because MAS bears a close similarity to the group of histiocytic disorders belonging to hemophagocytic lymphohistiocytosis (HLH), it is currently classified among the secondary, or acquired, forms of HLH (10, 11) . Along these lines, patients with sJIA who develop MAS may share similar genetic propensities as those with primary HLH (2) .
Timely diagnosis of MAS is critical to start therapy before damage related to hypercytokinemia becomes irreversible. However, there is no single feature that is specific for MAS, including hemophagocytosis (12) . Furthermore, MAS can be hard to distinguish from conditions that may present with overlapping features, such as flares of sJIA, sepsis or sepsis-like syndromes, or adverse effects of anti-arthritis medications. Differentiation of MAS from these 6 conditions is fundamental to selecting the appropriate therapeutic interventions in a timely fashion.
The difficulties in making the diagnosis emphasize the importance of reliable criteria that aid physicians in identifying MAS in its earliest stages and distinguishing it from confusable conditions. Two sets of guidelines are currently available for diagnosing MAS in patients with sJIA. The recognition that the syndrome is clinically similar to HLH has led some to recommend the use of the HLH-2004 guidelines, which were developed primarily for homozygous genetic disorders leading to hemophagocytosis (13) . An alternative approach is based on the application of the preliminary diagnostic guidelines for MAS complicating sJIA, which were created through the analysis of a cohort of patients with MAS compared with a group of patients with a flare of sJIA (14) .
Although both guidelines are considered potentially suitable for detecting MAS in sJIA, it has been argued that each of them is affected by a number of potential shortcomings (2, 11, 15, 16) .
However, the diagnostic performance of the two sets of guidelines has never been scrutinized using real patient data. For this reason, the present study was aimed to compare the capacity of HLH-2004 guidelines and preliminary MAS guidelines to differentiate sJIA-associated MAS from 2 potentially confusable conditions, represented by active sJIA without MAS and systemic infection.
PATIENTS AND METHODS

Study design and patient selection. Pediatric rheumatologists belonging to the Pediatric
Rheumatology International Trials Organization (PRINTO), the Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Childhood Arthritis and Rheumatology Research Alliance (CARRA), and pediatric hemato-oncologists belonging to the Histiocyte Society were 7 contacted by e-mail and invited to participate in a retrospective cohort study of patients with sJIAassociated MAS and with 2 conditions potentially confusable with MAS, represented by active sJIA without evidence of MAS and systemic infection, with data recorded in their hospital's database.
To facilitate enrolment of patients with systemic infection, investigators were asked to involve infectious disease specialists practicing at their hospital.
To be included in the study, patients with MAS had to have been diagnosed as having sJIA according to the International League of Associations for Rheumatology (ILAR) (17) Investigators were asked to include in the study only the patients seen after 2002. This time frame was chosen because the full awareness of the typical clinical and laboratory features of MAS was achieved in the early 2000s. In case the patients had multiple episodes of MAS, only the first episode had to be selected. Likewise, only one episode per patient had to be included for both patients with active sJIA without MAS and systemic infection.
The study protocol was approved by the Institutional Review Board at each participating center.
8 Data collection procedure. Investigators who agreed to participate in the study were asked to complete a structured case report form with each patient's anonymous data and then to enter the data into a electronic web-based database developed and handled at the coordinating center (the Istituto G. Gaslini of Genoa, Italy). For the purposes of the present study, the following information was collected for both MAS and control patients: demographic data, clinical manifestations, laboratory parameters, and histopathologic features. Demographic data included sex and age at onset of the disease. Clinical and laboratory data included those that are known to be most relevant for the diagnosis of MAS (19) . In patients with MAS, clinical and laboratory data were collected at onset of the syndrome, that is, at the time when the first signs or symptoms consistent with MAS were detected. The histopathologic section asked whether bone marrow aspirate or other biopsies were performed and, in case any of these procedures were done, whether evidence of macrophage hemophagocytosis was detected.
HLH-2004 diagnostic guidelines (13).
According to the Histiocyte Society's updated guidelines, a diagnosis of HLH can be established either by a molecular diagnosis with specific gene mutations associated with HLH or by meeting 5 of 8 clinical and laboratory diagnostic criteria for nonfamilial HLH. These criteria include fever; splenomegaly; peripheral blood cytopenias affecting at least two of three cell lineages; hypertriglyceridemia or hypofibrinogenemia; microscopic evidence of hemophagocytosis in the bone marrow, spleen, or lymphnodes; low or absent natural killer (NK) cell activity; elevated ferritin; and elevated soluble CD25 (sCD25; i.e. interleukin-2 receptor).
Because information about presence of hemophagocytosis was not available for both control groups and neither NK-cell activity nor sCD25 levels were determined in all patients, the diagnostic rule was modified to enable the diagnosis of HLH when either 3/5 or 4/5 of the remaining criteria trade-off between sensitivity and specificity were taken as cutoffs. For each cutoff, the sensitivity, specificity, area under ROC curve (AUC-ROC) and 95% confidence interval (CI), and diagnostic odds ratio (DOR) were calculated. The DOR of a test is the ratio of the odds of positivity in subjects with the disease to the odds of positivity in subjects without the disease; the value of DOR ranges from 0 to infinity, with higher values indicating better performance of a discriminatory test (22) .
Values of laboratory biomarkers were not normalized as neither the HLH-2004 guidelines nor the preliminary MAS guidelines require normalization.
RESULTS
The study sample included 362 patients with sJIA-associated MAS, 404 patients with active sJIA without MAS, and 345 patients with systemic infection, who were enrolled by 95 pediatric rheumatologists or hemato-oncologists practicing in 33 countries in 5 continents. The demographic data as well as the frequency of clinical features in MAS and control patients are presented in Table 1 . The proportion of females and the age at onset of sJIA were comparable between patients with MAS and patients with sJIA without MAS. All clinical manifestations were much more common in the MAS cohort than in both control groups, with the exception of fever, The frequency of individual 2004-HLH criteria in each patient sample is presented in Table 3 .
As expected, fever did not discriminate between the patient groups as it was recorded in nearly all patients in each cohort. All the other criteria were more common in patients with MAS than in control patients. However, the frequency of the criterion cytopenia in patients with MAS was very low (21.4%), owing to the stringent threshold value of blood cell counts. For the same reason, the criterion hypofibrinogenemia was met in only 24.8% of MAS cases. Although a ferritin level ≥ 500 ng/mL was detected in around 90% of patients with MAS, it was also recorded in a sizeable percentage (50.4%) of patients with sJIA without MAS. Table 4 illustrates the frequency of the individual items of preliminary MAS guidelines in the 3 patient samples. All criteria had a much greater prevalence in patients with MAS than in each control group. Notably, in patients with MAS decreased platelet count and increased aspartate HLH-2004 guidelines had maximum specificity, but poor sensitivity, whereas the original preliminary MAS guidelines were highly sensitive, but poorly specific. Table 6 shows the cutoff values, calculated through the ROC curve analysis, as well as the sensitivity, specificity, AUC and 95% CI, and DOR of each individual laboratory test for the The laboratory test that discriminated best between patients with MAS and patients with systemic infection was ferritin, followed by lactate dehydrogenase, liver transaminases, platelet count, and albumin (see supplementary online Table S1 Although the stringency of the threshold levels for cytopenia and hypofibrinogenemia may enhance the specificity of HLH-2004 guidelines, other items may be poorly specific. The criterion fever did not discriminate between MAS and control patients as this feature was recorded in all or nearly all patient in each sample. Unfortunately, we could not obtain reliable information on the pattern of fever. However, it is common view that the onset of MAS is often heralded by the shift from the high-spiking intermittent pattern typical of active sJIA to a continuous unremitting pattern (3) (4) (5) (6) . The criterion ferritin ≥ 500 ng/mL was present in 89.9% patients with MAS, but also in 50.4% of patients with sJIA without MAS, which suggests that such threshold level may not discriminate MAS from active sJIA. It is well known that many patients with active sJIA, in the absence of MAS, have ferritin levels above that threshold (24) . In the acute phase of MAS, ferritin levels may peak to more than 5,000 ng/mL or even 10,000 ng/mL. Thus, a ferritin threshold greater than 500 ng/mL may be better suited to detect MAS in sJIA.
Hemophagocytosis was identified in 63.5% of MAS patients who had a bone marrow aspirate or a reticuloendothelial organ biopsy performed. Considering that in 30.4% of cases tissue confirmation was not looked for, the frequency of positive histopathologic findings in the entire MAS sample was only 44.2%. Hemophagocytosis is known to be frequently absent in both HLH and MAS, particularly in their initial stages (25, 26) . Recently, isolated hemophagocytosis in marrow core biopsy specimens or aspirates was found to lack specificity for HLH (12) . Notably, the demonstration of hemophagocytosis is not mandatory in both HLH-2004 and preliminary MAS guidelines.
The good diagnostic performance of the preliminary MAS guidelines was due to the strong ability of all individual criteria to discriminate between MAS and sJIA without MAS. However, among laboratory criteria, the items decreased platelet count and increased aspartate The adapted 4/5 HLH-2004 guidelines had maximum specificity, but poor sensitivity, whereas the original preliminary MAS guidelines were highly sensitive, but poorly specific. In the analysis of cutoff values of laboratory tests that provided the best discrimination between MAS and sJIA without MAS, the parameters that reached an AUC > 0.80 were platelet count, liver transaminases, lactic dehydrogenase, triglycerides, fibrinogen and ferritin. These biomarkers may be the best candidates for inclusion among laboratory criteria in a future revision of the MAS guidelines. The cutoff for ferritin (1040 ng/mL) revealed good sensitivity, but modest specificity.
This implies that ferritin alone may not be sufficient to detect MAS as some patients with active sJIA without MAS may have a level above such a threshold. However, the application of a higher threshold may decrease sensitivity, that is, may lead to exclusion of some instances of MAS. The laboratory parameters whose cutoff reached an AUC > 0.80 in the discrimination between MAS and systemic infection were liver transaminases, lactate dehydrogenases and ferritin. It is noteworthy that the discriminative potential of ferritin at 394.1 ng/mL was very strong, with both sensitivity and specificity above 0.9 and an AUC of 0.97. In addition, only the MAS group as a whole demonstrated a ferritin to ESR ratio of >80, which has been suggested to distinguish MAS from new onset sJIA flare (27) . However, the large majority of the patients were diagnosed in tertiary care referring centers. sJIA = systemic juvenile idiopathic arthritis; MAS = macrophage activation syndrome; AUC area under the curve; CI = confidence interval; DOR = diagnostic odds ratio.
